Broad-spectrum antiviral from Gilead, delivered by IV
A Bundibugyo Ebola outbreak is driving rapid development of vaccines and antibody therapies. Doses of MBP134 are being used for compassionate use and clinical trials, while several vaccine candidates are advancing toward human testing. Trials face challenges from battlefield-like conditions in eastern Congo and Uganda.
Health authorities have reported at least 1,759 confirmed Ebola cases and about 600 deaths in the Democratic Republic of Congo since mid-May, driven by the rare Bundibugyo strain. The World Health Organization has enrolled the first patient in a trial testing MBP134 and remdesivir; treatment centres are strained and insecurity and funding shortfalls are hindering response.
Frontline workers at Ituri’s Ebola response facilities have struck over unpaid wages as the Bundibugyo outbreak expands to more provinces. The situation adds strain to an already overwhelmed health system, with clinics at capacity and mistrust hampering containment efforts. New cases have been confirmed in Haut-Uele and Tshopo, raising the outbreak’s regional footprint.
UK volunteers are joining a phase 1 trial to test the safety and immune response of the ChAdOx1 BDBV vaccine against Bundibugyo Ebola. The trial follows the DRC outbreak and uses the same tech as the Oxford/AstraZeneca Covid vaccine. Doses have been stockpiled, and collaboration with Uganda continues as researchers move toward later-stage studies.